Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Thyroid Nodule 1Prostatic Neoplasms 1Multiple Pulmonary Nodules 1Hyperaldosteronism 1Carcinoma, Renal Cell 1Bone Cancer Metastatic 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Specimen Handling 4Endoscopy, Digestive System 2Endoscopy 2Biopsy 2plecanatide 1obeticholic acid 1linaclotide 1Spectrum Analysis 1Risk Assessment 1Radiofrequency Ablation 1Mass Screening 1Itraconazole 1Gastroscopy 1Cetuximab 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Barrett Esophagus × Radiofrequency Ablation × 90 days × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡